Translational Imaging in Drug Safety Assessment

derive MRI and CT-based Imaging Biomarkers, IB from well-characterised rheumatology and oncology patients who develop Drug induced Interstitial Lung Disease, DIILD during standard-of-care drug treatment;
 establish pathological correlates of these MRI and CT-based IBs in animal models, initially a bleomycin rat model;
 establish cross-sectional clinical correlates of these MRI and CT-based IBs;
 determine how well these MRI and CT-based IBs track progression and resolution of DIILD in these patients;
 determine how well these MRI and CT-based IBs forecast clinical outcome in these DIILD patients;
 establish the benefit of these MRI and CT-based IBs over existing non-imaging assays;
 make these MRI and CT-based IB assays commercially available both in man in a multicentre setting, and
also in rat, on a non-exclusive basis;
 extend our ability to characterise human DIILD by innovating IBs derived from 1H/129Xe MRI;
 extend our ability to characterise human DIILD by innovating PET, MRI or MRS IBs of fibrosis,
macrophages, vascular permeability/leakage, neutrophil infiltration, and activated T cell infiltration;
 evaluate the best of these innovative IBs in rats and humans;
 (as appropriate) make these innovative IB assays commercially available both in man in a multicentre setting, and also in rat, on a non-exclusive basis.

Utveckla metoder med bildgivande tekniker för att hitta biverkningar av läkemedel på lunga.